ADCendo ApS | MedPath

FDA Clears IND for Adcendo's Novel Tissue Factor-Targeting ADC in Advanced Solid Tumors

3 months ago

• Adcendo's ADCE-T02, a first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate targeting tissue factor, receives FDA clearance to begin Phase I trials in advanced solid tumors. • The Tiffany-01 trial, currently recruiting in Australia and expanding to the U.S., will evaluate safety, pharmacokinetics, and preliminary efficacy of ADCE-T02 in patients with advanced solid tumors. • The drug's unique design aims to overcome limitations of existing tissue factor-targeting ADCs by offering an improved therapeutic window and better safety profile for multiple cancer indications.